Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation

Highlights • Endocannabinoid augmentation may have broad therapeutic implications. • COX-2 is a third endocannabinoid metabolic mechanism. • Substrate-selective COX-2 inhibition increases central endocannabinoid signaling. • Substrate-selective COX-2 inhibition decreases anxiety.

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2014-07, Vol.35 (7), p.358-367
Main Authors: Hermanson, Daniel J, Gamble-George, Joyonna C, Marnett, Lawrence J, Patel, Sachin
Format: Article
Language:English
Subjects:
Advanced Basic Science
Animals
Cannabinoids - metabolism
Cyclooxygenase 2 - metabolism
Cyclooxygenase 2 Inhibitors - pharmacology
Humans
Signal Transduction - drug effects
Substrate Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Endocannabinoid augmentation may have broad therapeutic implications. • COX-2 is a third endocannabinoid metabolic mechanism. • Substrate-selective COX-2 inhibition increases central endocannabinoid signaling. • Substrate-selective COX-2 inhibition decreases anxiety.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2014.04.006